Nucleosome blood test for first lymphoma treatment
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study is looking at a new blood test that measures tiny DNA particles (called nucleosomes) in patients with two types of lymphoma who are about to start standard first treatment. The goal is to see if the test can help predict how well treatment works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have either a diagnosis of diffuse large B cell lymphoma or follicular lymphoma (types of lymphoma).
- You must be about to start your very first treatment (first line) with a specific chemo + antibody regimen called RCHOP 21.
- You have not received any previous treatment for lymphoma, except possibly low-dose radiation for a single area in follicular lymphoma.
- You agree to participate in the study and sign a consent form after receiving information.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects blood and tumor tissue samples from people newly diagnosed with aggressive non-Hodgkin lymphoma who will receive standard chemotherapy. The goal is to improve future tests for detecting minimal residual disease (tiny amounts of cancer left after treatment).
This study uses special lab testing (“omics”) on people with certain fast-growing B-cell lymphomas to find results that can help with diagnosis and predicting outcomes. It may help by improving how clinicians identify the lymphoma type and forecast how it may behave.
This trial studies whether using a blood test (ctDNA) can help guide treatment decisions for people with newly diagnosed diffuse large B-cell lymphoma. It tests standard chemotherapy regimens (R-CHOP or R-pola-CHP) and aims to improve outcomes by monitoring tumor DNA in the blood.
This study looks for tumor “signatures” (including tiny RNA molecules, or miRNA) to predict outcomes in people with relapsed or resistant diffuse large B‑cell lymphoma (DLBCL). Your tissue samples help researchers see which patients may benefit from standard chemotherapy plus antibody treatment.
This trial uses a blood test to look for tumor DNA in people with high-risk B-cell lymphoma, to help predict if the lymphoma might spread to the brain or spinal cord. It may help doctors decide on extra treatments to prevent that spread.
This study looks at whether blood tests for tumor DNA (cfDNA) can help guide treatment decisions for people with newly diagnosed DLBCL. It focuses on patients who achieve complete remission after 6 rounds of R-CHOP chemotherapy.
Hear when a new Follicular Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.